Elevai Labs highlights results from preclinical studies on EL-22

Elevai Labs highlights results from its licensor’s 2022 preclinical studies evaluating the treatment effect of its recently in-licensed asset, EL-22. EL-22 will primarily be commercialized by Elevai Biosciences, a biopharmaceutical division of the Company focusing on the development and acquisition of cutting-edge aesthetic medicines. Based on our licensor’s 2022 preclinical data, Elevai believes that EL-22 has the potential to treat obesity in combination with GLP-1 receptor agonists by preserving muscle mass while decreasing fat mass. Specifically, in the preclinical studies: EL-22 showed a statistically significant increase in anti-myostatin IgG antibody concentration, where myostatin is a key negative regulator of muscle growth. Statistically significant decrease in creatine kinase levels, which indicates a decrease of muscle destruction. EL-22 administered to mdx mice, a mouse model of Duchenne muscular dystrophy, had improved physical activity and gross motor function, as demonstrated by a longer duration during rotarod tests.